Hinge Health launched its Enso 3 FDA-cleared wireless device for reducing musculoskeletal pain. San Francisco-based Hinge designed the device to deliver electrical nerve stimulation for non-invasive, non-addictive pain relief within minutes. The company plans to start the first shipments of the new Enso device this month. It then expects wider availability to all new Hinge Health members starting in 2025.
Related: US FDA approves Resivant Medical’s tissue adhesive products
The new Enso.3 device features reimagined hardware with new colors, finish and materials. Small and light, Enso 3 attaches to the skin with a reusable gel pad for comfortability before exercise therapy or during daily activities affected by pain.
Hinge also introduced new, clinically proven electrical waveforms customized to different body parts and pain levels. The company programmed the patterns of electrical signals through software to relieve pain. It also features two new waveforms targeting smaller muscles, also aiding people with more sensitivity.
Enso 3 can also offer new treatments over time with over-the-air software updates for new waveforms released in the future. Hinge integrated new features into its all-in-one app to help with guidance and progress tracking.
The company recently reported results from a randomized, controlled trial of 325 participants. In that trial, Enso showed superior pain reduction compared to a traditional transcutaneous electrical nerve stimulation (TENS) device and exercise therapy alone.
“A musculoskeletal solution is incomplete without an effective way to help people overcome pain that disrupts their daily activities,” said Daniel Perez, CEO and co-founder of Hinge Health. “We’re thrilled to be shipping this unparalleled hardware-software medical solution to Hinge Health members, empowering them with the industry’s most advanced pain relief device that’s seamlessly integrated with the world’s leading exercise therapy program.”
